These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16504957)

  • 1. Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients.
    Brockmeyer NH; Poffhoff A; Bader A; Hochdorfer B; Schlottmann R; Rasokat H; Altmeyer P; Kreuter A
    Eur J Med Res; 2006 Jan; 11(1):27-32. PubMed ID: 16504957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Peg-interferon alfa-2a and highly active antiretroviral drug therapy on hepatitis C patients with AIDS].
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Lu HZ
    Zhonghua Gan Zang Bing Za Zhi; 2007 Oct; 15(10):734-7. PubMed ID: 17963597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
    Voigt E; Schulz C; Klausen G; Goelz J; Mauss S; Schmutz G; Jessen H; Weitner L; Mutz A; Schranz D; Rockstroh JK;
    J Infect; 2006 Jul; 53(1):36-42. PubMed ID: 16269184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus.
    Aguilar Marucco D; Veronese L; de Requena DG; Bonora S; Calcagno A; Cavecchia I; Sinicco A; De Rosa FG; Cariti G; Di Perri G
    J Antimicrob Chemother; 2007 Mar; 59(3):565-8. PubMed ID: 17213263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
    Fumaz CR; Muñoz-Moreno JA; Ballesteros AL; Paredes R; Ferrer MJ; Salas A; Fuster D; Masmitjà E; Pérez-Alvarez N; Gómez G; Tural C; Clotet B
    AIDS Care; 2007 Jan; 19(1):138-45. PubMed ID: 17129869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
    Glesby MJ; Bassett R; Alston-Smith B; Fichtenbaum C; Jacobson EL; Brass C; Owens S; Sulkowski M; Race EM; Sherman KE;
    J Infect Dis; 2005 Mar; 191(5):686-93. PubMed ID: 15688281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A multicenter, randomized, open-label study of the safety and effectiveness of pegylated interferon alpha 2b and interferon alpha 2b in treating HBeAg positive chronic hepatitis B patients].
    Zhao H; Si CW; Wei L; Wan MB; Ying YK; Hou JL; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2006 May; 14(5):323-6. PubMed ID: 16732903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient.
    Bessis D; Charron A; Rouzier-Panis R; Blatière V; Guilhou JJ; Reynes J
    Eur J Dermatol; 2002; 12(1):99-102. PubMed ID: 11809610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
    Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
    Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
    Fuster D; Planas R; Gonzalez J; Force L; Cervantes M; Vilaró J; Roget M; García I; Pedrol E; Tor J; Ballesteros AL; Salas A; Sirera G; Videla S; Clotet B; Tural C
    Antivir Ther; 2006; 11(4):473-82. PubMed ID: 16856621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; Marxuach-Cuétara AM; López-Torres A; Jiménez-Rivera J
    J Hepatol; 2007 Apr; 46(4):613-9. PubMed ID: 17316873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.